Heterozygous Gnaq deficiency enhances Ifi202b/IFI16 and NF-κB activation in endothelial cells and exacerbates lupus nephritis pathology.

iScience

Department of Rheumatology and Clinical Immunology (Xiamen Municipal Clinical Research Center for Immune Diseases, Xiamen Key Laboratory of Rheumatology and Clinical Immunology), The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Published: August 2024

Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), exhibits significant heterogeneity. Recent evidence suggests that non-immune factors contribute to end-organ damage, challenging the traditional view of LN solely arising from immune dysregulation. To investigate this, we employed autoimmune-prone mice receiving intraperitoneal pristane injections. Bone marrow transfer (BMT) distinguished the roles of immune versus non-immune cells. We observed that: (1) BMT from wild-type (WT) mice to recipients resulted in severe proteinuria and diffuse proliferative nephritis after pristane exposure; (2) GNAQ knockdown increased the expression of IFI16/Ifi202b and activated the NF-κB pathway in endothelial cells; and (3) increased IFI16 expression in human kidney biopsies correlated with proliferative LN. Taken together, these findings suggest that GNAQ acts as an inflammatory regulator in kidney endothelial cells via the IFI16/NF-κB pathway, potentially linking it to the development of LN in humans.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301098PMC
http://dx.doi.org/10.1016/j.isci.2024.110350DOI Listing

Publication Analysis

Top Keywords

endothelial cells
12
lupus nephritis
8
heterozygous gnaq
4
gnaq deficiency
4
deficiency enhances
4
enhances ifi202b/ifi16
4
ifi202b/ifi16 nf-κb
4
nf-κb activation
4
activation endothelial
4
cells
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!